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RÉSUMÉ 
Le cancer de la prostate est souvent traité par la résection de la prostate entière, une procédure 
appelée prostatectomie radicale. Le succès de cette procédure dépend de la capacité du chirurgien 
a retirer la totalité de la prostate et à assurer qu’il ne reste aucunes cellules cancéreuses à la marge 
chirurgicale. On retrouve du cancer à la marge dans jusqu’à 20% des procédures et à ce jour, les 
marges ne sont évaluées par un pathologiste que plusieurs heures après la chirurgie nécessitant des 
traitements adjuvants quand du cancer est détecté. La capacité de caractériser du tissue de façon 
intra opératoire et en temps réel est donc un réel besoin clinique qui n’est pas comblé par la 
technologie actuelle. La spectroscopie Raman est une technologie optique basée sur la diffusion de 
la lumière par des molécules et liens moléculaires spécifiques. La spécificité moléculaire de la 
spectroscopie Raman peut être couplée à des techniques d’apprentissage machine pour effectuer 
de la caractérisation de tissu en fonction de sa composition moléculaire. Ceci pourrait combler le 
besoin clinique énoncé en permettant aux chirurgiens de détecter et retirer le maximum de tissu 
prostatique bénin et cancéreux. Dans ce mémoire, nous présentons la conception et le 
développement d’un système de spectroscopie Raman intégré à une plateforme de chirurgie 
robotisée couramment utilisée pour effectuer des prostatectomies. L’ingénierie du système et sa 
validation sur des fantômes sont d’abord présentés. Nous présentons ensuite une preuve de concept 
effectuée sur 20 prostates humaines ex vivo pour démontrer la capacité du système à distinguer 
entre du tissu de prostate et du tissu extra-prostatique avec une précision, sensibilité et spécificité 
tous au-delà de 90%.  Finalement, nous présentons l’utilisation du système avec une plateforme de 
chirurgie robotisée pour effectuer, pour la première fois, des mesures de spectroscopie Raman in 
vivo sur des prostates humaines pendant la prostatectomie.  
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ABSTRACT 
Prostate cancer is often treated through a radical prostatectomy procedure consisting of the removal 
of the entirety of the prostate gland. The success of this procedure relies on the surgeon’s ability to 
resect prostate tissue maximally and ensure no cancer is left behind. Surgical margins are currently 
assessed by pathologists only hours to days following surgery and positive surgical margins (cancer 
cells having spread to the boundary of resection) occur in as many as 1 in 5 cases.   The ability to 
characterize tissue intraoperatively, in real time is therefore an important clinical need and is unmet 
by current technology. Raman spectroscopy (RS) is an optical technology based on the scattering 
of light by specific molecules/molecular bonds. Combining the molecular specificity of RS with 
machine learning techniques has shown promise for tissue characterization based on molecular 
composition. This sort of molecular fingerprinting could benefit prostatectomy procedures by 
ensuring maximal resection of prostate tissue and cancer.  In this thesis, we present the design and 
development of an RS system integrated to a surgical robotics platform commonly used in RP. 
Design, engineering, and validation work on phantoms is presented. A proof of concept study was 
performed to demonstrate the ability of RS to characterize prostate tissue wherein the system was 
used to obtain data on 20 whole human prostates ex vivo. Preliminary results show successful 
distinction between prostatic and extra-prostatic tissue with accuracy, sensitivity and specificity 
over 90%. Also presented is the successful use of the system with a surgical robot to perform in 
vivo measurements in humans on 5 patients for the first time.  
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CHAPTER 1 INTRODUCTION 
1.1 Prostate Cancer, treatment, and clinical motivation   
Prostate cancer  occurs when cells from the prostate gland begin to grow uncontrollably. It is the 
second most frequently diagnosed cancer globally[1] . In the United States in 2015 there were an 
estimated 220,800 new prostate cancer cases (26% of all 2015 cases) and 27,540 deaths (9% of all 
2015 estimated cancer deaths)[2] .  
 
Figure 2.1 : Human reproductive anatomy with closeup view of prostate and prostate cancer. 
Source : https://www.cancer.org/cancer/prostate-cancer/about/what-is-prostate-cancer.html 
Surgical excision of the whole prostate through Radical Prostatectomy (RP) is an important 
standard of care for prostate cancer and can be performed through open (ORP), laparoscopic (LRP) 
or robotic assisted (RA-RP) surgical methods. Minimally invasive techniques such as LRP and 
RA-RP have comparable clinical outcomes to ORP. However, RA-RP leads to shorter 
catheterization times and hospital stays, less blood loss and reduced complication rates[3]. 
Moreover, the robots used for RA-RP offer a platform well suited for the integration and control 
of assistive technologies with minimal perturbation to the surgeon’s workflow.   
The clinical objective of the procedure is to remove the entire prostate while sparing nerves and 
other surrounding tissues. This presents surgeons with several clinical challenges unmet by present 
technology. Firstly, removing the whole organ is made difficult by the lack of clear histological 
prostate capsule leading to prostate tissue left behind in as many as 29% of cases[4]. Moreover, 
positive surgical margins (cancer cells having spread into surrounding marginal tissue) occur in as 
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many as 1 in 5 cases and strongly correlate with disease recurrence[5]. Positive surgical margins 
are only discovered following surgery, when pathologists study the excised prostate. Finally, 
detection of nerves vital to erectile and urinary function could lead to more effective nerve sparing 
which has important impacts on post-operative erectile function and urinary continence[6]. As 
such, there is an important clinical need for a real time, in vivo method to characterize tissue during 
RP to insure more complete resections, detect cancer at the margin and lead to better outcomes 
with regards to urinary continence and erectile disfunction.  
1.2 Raman spectroscopy for tissue characterization  
Raman spectroscopy (RS) is an  optical technology that has shown promising results for sensitive 
and specific molecular characterization of tissue[7][8]. RS is based on the detection of inelastically 
scattered light following tissue excitation with monochromatic light[9]. When light is incident on 
tissue, the most probable interaction process is elastic scattering (Rayleigh scattering) resulting in 
light reemission at the same frequency as the excitation. The Raman effect is associated with a 
small fraction of the reemitted light instead being scattered at a frequency different from that of the 
incident photons. The resulting spectral shifts are associated with molecular vibrations and provide 
an avenue for precise and quantitative fingerprinting since each molecular species have their own 
spectral signature. A more detailed overview of Raman spectroscopy and its clinical applications 
is presented in section 2 of this thesis.  
Previous work performed using RS shows great promise for its use as a diagnostic tool. For 
example RS has been shown to detect high grade glioblastoma (brain cancer) in vivo during surgery 
where it successfully differentiated normal brain from cancer tissue in 17 patients with grade 2-4 
gliomas with a sensitivity of 93% and a specificity of 91% (as compared to standard H&E 
analysis)[10]. More specific to prostate cancer, RS has been shown to identify prostate cancer with 
high accuracy in vitro and  ex vivo (see section 2.3 for a detailed review on the subject) though, to 
our knowledge, no studies have performed in vivo RS characterization of prostate tissue.  
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1.3 Research objectives  
The general objective of this thesis is to demonstrate that a RS can be integrated into the da Vinci 
surgical platform for RA-RP to collect RS spectra at the surgical margin during RA-RP with the 
aim of characterizing tissue composition. An emphasis is placed on the engineering and integration 
work required to integrate RS with RA-RP and preliminary results on both ex vivo and in vivo 
datasets gathered using this system are presented. The central hypothesis supporting this work is 
that RS could be used during RA-RP and has potential for prostate tissue 
characterization/classification. To test this hypothesis, the objectives of this research project are 
listed below :  
Objective 1: Integrate RS into the da Vinci surgical robotics platform 
Objective 1.1 : Perform hardware and software engineering necessary for robotic integration of RS 
to the da Vinci surgical platform  
Objective 1.2 : Verify and validate integration using a phantom of known molecular composition 
and geometry 
Objective 2: Collect ex vivo and in vivo Raman spectra from human prostate and peri 
prostatic organs/tissues  
Objective 2.1 : Collect Raman spectra from whole, unprocessed prostates immediately following 
RP with the objective characterising Raman spectra in different prostatic regions 
Objective 2.2 : Collect Raman spectra from prostate and peri-prostatic organs in vivo to assess the 
feasibility of distinguishing between prostatic and peri-prostatic tissue intra operatively 
Objective 2.3 : Automate the process of acquiring Raman spectra from cross sectional prostate 
slices following RP with the objective of distinguishing between benign and malignant prostatic 
tissue in a manner that is independent of the heterogeneous molecular background associated with 
the prostate.  
 
Objective 3: Classify and characterize tissue based on acquired datasets 
Objective 3.1 : Train algorithms capable of differentiating prostatic from peri-prostatic tissue 
Objective 3.2 : Compare ex vivo and in vivo spectra 
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CHAPTER 2 BACKGROUND THEORY & LITERATURE REVIEW 
2.1 Raman Scattering & the Raman spectrum  
Light (photons) incident on a sample (be it solid, liquid, or gas) will be scattered by atoms or 
molecules which make up the medium and are of much smaller size than the light source 
wavelength. The electric field from an incident photon induces oscillating polarizations in the 
molecular bonds of the medium, bringing the molecules to a virtual energy state higher than its 
permitted vibrational states. This virtual energy state can then interact with the molecules permitted 
vibrational states. The first (and most likely) type of interaction is for the molecules to return to 
their original state (the most probable being the ground state) emitting a photon with the same 
frequency and wavelength as the light source. This phenomenon is referred to as elastic scattering 
(also referred to as Rayleigh scattering)[11]. Another form of scattering, inelastic or Raman 
scattering was first postulated by Smekal in 1923[9] and observed experimentally in 1928[12] by 
Indian scientist C.V Raman and his student K. S Krishnann. They observed that when a sample is 
excited with a light source of a given wavelength, a much weaker spectrum composed of peaks of 
light of wavelengths higher and lower than the excitation wavelength is emitted. These emissions 
are the result of interactions between a virtual energy state and vibrational energy states different 
from the one the molecule was in when it encountered the photon. The molecule ends in a 
vibrational state higher or lower than the one it was in before interaction (either absorbing energy 
or transferring some in the process) and a photon of either higher or lower wavelength than the 
incident one is emitted. This process is known as inelastic scattering (also referred to as Raman 
scattering). A molecule that is left in a higher vibrational state will scatter a photon with lower 
energy (referred to as Stokes Raman scattering) than the incident one and one in which the molecule 
is left in a lower vibrational state than it began in will scatter a photon with higher energy (referred 
to as anti-Stokes Raman scattering) than the incident one. Since molecules are far more probable 
to be in lower vibrational states when they scatter a photon, Stokes Raman scattering is more 
intense than its anti Stokes counterpart and will be the focus of this work.  
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Figure 2.1 : Visual depiction of possible interactions between vibrational and virtual energy states 
following excitation with monochromatic light. Source : 
https://commons.wikimedia.org/wiki/File:Raman_energy_levels.svg 
The different molecules and molecular bonds that make up a sample excited by monochromatic 
light will each have different vibrational/virtual energy states and will therefore result in the 
emission of photons of distinct wavelengths around the excitation one. Using a spectrometer and 
specialized equipment to collect this light, it is possible to record the spectrum of light emitted by 
an excited sample: the Raman spectrum. Since Raman scattering is so deeply related to the 
molecular make-up of the scattering material, the spectrum of light generated can be used as a sort 
of molecular fingerprint: this is the basis of Raman spectroscopy. Raman spectra are typically 
expressed in terms of shifts from the excitation wavelength (Raman shifts) and have units of 
wavenumbers since the spectrum is independent of excitation wavelength. The spectral range of 
Raman shifts from 400 – 1800 cm-1 is typically referred to as the “Fingerprint” (FP) region while 
the range of Raman shifts from 2000-3000 cm-1 is commonly referred to as the “high-wavenumber” 
(HWN)  region.  Figure 3 shows the Raman spectrum for a sample of acetaminophen (more 
commonly known as Tylenol) :  
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Figure 2.2 : Typical acetaminophen (Tylenol) Raman spectrum in the FP region. Acetaminophen 
is commonly used as a reference in literature. Source : 
https://commons.wikimedia.org/wiki/File:Acetominophen_Raman.jpg 
It is worth noting that Raman scattering is a very rare effect (approximately 1 in 106 photons) that 
is in direct competition with other interactions between light and samples. Most notably for Raman 
spectroscopy of biological samples, the Raman spectrum is several orders of magnitude smaller 
than auto-fluorescence caused by the interaction between fluorophores present in the sample and 
light[13].   
Raman spectroscopy systems share the same core components: a monochromatic excitation source, 
an optical device which delivers the excitation light to the sample and collects the spectral response, 
a high throughput spectrometer and a highly sensitive CCD detector to digitize the spectral 
response[14]. Recent technological advances in each of these components allows the development 
of systems which are compatible with clinical use. Notably, wavelength stabilized monochromatic 
lasers, high throughput and resolution spectrometers and highly sensitive CCD detectors have 
allowed the collection of a Raman spectrum at reasonable time scales (a couple of seconds)[15]. 
Moreover, advances in fiber optic light delivery/collection and miniaturized optical elements/filters 
have allowed the development probes which are capable of delivering excitation light and 
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collecting a spectral signature while filtering out the predominant Rayleigh scattering from 
excitation. The use of fiber optics and miniature filters has allowed the development of probes 
which can deliver/collect light several meters from the excitation source/detector making them 
suitable as handheld probes in a sterile surgical field.  
2.2 Spectral processing and classification  
Collecting spectra is not enough for effective use of RS as a clinical tool. Spectra need to be 
analyzed and transformed into easily interpretable and clinically relevant information. Uncovering 
the subtle molecular differences that mark the difference between, for example, spectra from 
healthy and diseased tissue, requires a large dataset of properly processed and labeled spectra. The 
first step to gathering a dataset is to determine appropriate strategy to establish ground truth in 
labels. There should be an observable molecular difference that exists between classes and a way 
to ensure it is properly labeled across spectra. For example, analysis of samples interrogated can 
be performed by a histopathologist to provide ground truth in distinguishing between spectra from 
benign and malignant tumors, cell lines of known origins can be cultured and measured, spectra 
can be acquired from specific anatomical structure, etc. It is worth noting that the accuracy of the 
method chosen in labeling for ground truth poses a limitation on the accuracy of any following 
classification methods. Once ground truth is established, the use of automated machine learning 
approaches requires sufficiently large datasets to perform blinded validation and avoid over-fitting 
of the data (at least 75-100 spectra to test a “good but not perfect” classifier according to a recent 
study from Cornell university[16]). This is often an important hurdle in clinical applications where 
obtaining large quantities of spectra can be complicated, lengthy and costly. With a large labeled 
dataset, it is then important to perform appropriate spectral processing and normalization. Common 
preprocessing steps of Raman spectra exist for comparison of spectra across datasets (e.g across 
patients). These include noise reduction using smoothing filters or frequency-based analysis, auto-
fluorescence background removal to separate the Raman spectrum from excitation induced tissue 
auto-fluorescence[13][17], subtraction of an excitation free spectral acquisition to correct for 
ambient lighting, cosmic ray detection, normalization to compare spectra across datasets[18], and 
instrument response correction/calibration using a known standard[19] to compare datasets across 
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systems. Many different techniques exist for each one of these preprocessing steps which depend 
on specific applications/preferences and exceed the scope of this review. Specific techniques used 
in this publication are elaborated in  chapter 3 of this work.  
Finally, processed spectra may then be used for machine learning based approaches. Classifiers are 
trained on datasets with Raman spectra of known origin and used on unlabeled spectra to assess 
their performance. Multivariate differences in peak expressions/intensities across different classes 
of spectra lead to successful classification. A wide variety of techniques may be employed[20][21] 
which exceed the scope of this literature review though optimal classification is generally achieved 
by using automated approaches to detecting key features for separation of classes such as support 
vector machines (SVMs). The following chapter of this review will focus on specific examples 
while the techniques employed for this project are detailed in chapter 3.   
 
2.3 Diagnostic applications of Raman Spectroscopy in Oncology 
RS has been studied for a variety of clinical applications such as in the diagnosis of Alzheimer’s 
disease[22], nephropathic cystinosis [23], studying calcification in cardiovascular applications[24], 
[25],[25]. The focus of this review will be on oncological applications where currently available 
diagnostic tools for tissue characterization fail to address the needs of clinicians. These include 
H&E/histopathology on biopsy samples, computed tomography, magnetic resonance imaging and 
positron emission tomography scans and ultrasound. H&E/histopathology is lengthy, labor 
intensive, costly and can only provide results days following the surgery[26]. The other imaging 
techniques lack in sensitivity and specificity for cancer cell detection, can be very expensive, 
oftentimes rely on the use of an exogenous contrast agent, and can not be used in real time. RS is 
a label-free, minimally invasive and sensitive technique which can be used in real-time and holds 
great promise for applications in oncology. The following section will review literature in this 
domain with an emphasis on clinical applications in prostate and in vivo applications in humans. 
In prostate, RS has been shown to identify cancer with high accuracy. A few studies using Raman 
microscopy-based systems have successfully characterized prostate cancer tissue. Crow et al. first 
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suggested the use of RS in prostate in 2002 showing variations in expressions of peaks 
corresponding to glycogen and nucleic acids (1655 cm-1 and 1240-1265 cm-1) between spectra 
collected using a Raman microscope on benign prostatic hyperplasia (BPH) and prostatic 
adenocarcinoma[27]. A year later, this group conducted a study involving 27 patients showing RS 
could be used in vitro to identify BPH (sensitivity 93%, specificity 92%) , gleason scores (GS) <7 
(sensitivity 85%, specificity 96%), =7 (sensitivity 81%, specificity 96%) and >7 (sensitivity 94%, 
specificity 100%)[28]. This was accomplished using a linear discriminant analysis (LDA) classifier 
with a leave-one-spectrum-out cross validation approach. Crow et al. again demonstrated the 
potential of RS in vitro using a Raman microscope to differentiate (classification performed using 
LDA and leave-one-spectrum-out cross validation) between spectra from two well differentiated 
and two poorly differentiated cell lines with sensitivity and specificity at 96-100% and 99-100%, 
respectively[29]. Wang et al. have also demonstrated that a Raman microscope on two cell lines 
from 50 patients can successfully discriminate between androgen-dependant and castration-
resistant prostate cancer using an SVM trained with leave-one-out cross validation with a 
sensitivity of 88.2% and specificity of 87.9%[30]. Similar Raman microscopy studies have been 
performed on bladder breast, skin, oral, and a host of other cancerous tissues with equally 
promising results[31],[32]. These studies all suggest promise for the use of RS as a diagnostic tool 
though the use of RS through a microscope imposes significant limits on its clinical usefulness and 
viability. Microscopes require tissue preparation/fixation, have long acquisition times (in the order 
of 10 seconds to one minute per spectrum) and therefore fail to address the need of real time 
characterization in the operating room. As such, much work has been done to integrate RS to fiber 
optic probes. Due to the difficulty of acquiring histopathology ground truth in vivo most studies 
have been geared towards analyzing tissue ex vivo as a first step towards testing systems and probes 
compatible for in vivo use[33]. A 2005 study on snap-frozen bladder and prostate samples collected 
during surgery using a “fiberoptic Raman system suitable for in vivo use” was able to differentiate 
benign from malignant samples with an accuracy of 84% on bladder samples and 86% in prostate 
samples[34]. Previous work performed ex vivo thus shows promise for the application of RS to the 
characterization of prostate tissue.  
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 The past decade has been marked with important strides towards clinical translation of RS 
in vivo. Technological advances in CCD detectors, lasers, and fibered optics have allowed for 
spectral acquisitions with performance and time scales suitable for in vivo use[15]. Zhao et al  
conducted a large study on 289 patients where they performed measurements on suspect skin 
lesions with acquisition times under 1 second.  Using partial least squares regression and linear 
discriminant analysis on the spectra, they achieved 91% sensitivity and 75% specificity for 
differentiating skin cancers from benign legions and 97% sensitivity/78% specificity in 
differentiating malignant melanoma from benign pigmented lesions[35].  For more difficult to 
reach organs, RS has been integrated to a variety of endoscopic systems for investigative work 
[33]. Draga et al. used an RS probe to obtain Raman spectra from ‘suspicious’ and ‘nonsuspicious’ 
bladder locations with acquisition times under 5 seconds. They reported a sensitivity of 85% and 
79% in distinguishing normal from cancerous bladder locations[36]. In brain cancer, invasive 
cancer cells frequently remain after surgery, leading to disease recurrence and a negative impact 
on overall survival[10]. Our research group at Polytechnique Montreal has developed a handheld 
RS probe for intraoperative collection of Raman spectra[10]. The following figure shows a view 
of the handheld probe used during open cranium glioblastoma resection.  
 
Figure 2.3 :  Handheld RS probe developed by Prof. Leblond’s research group at Polytechnique 
Montreal in use during glioblastoma resection surgery 
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Using this probe, a study was conducted on 17 patients with gliomas of grade 2-4 with acquisition 
times on the order of 1 second. For each patient, measurements were collected in the surgical cavity 
by placing the probe in contact with tissue of unknown origin. The surgeon then took a biopsy 
where the probe left an indentation which underwent histopathological analysis and was classified 
as being “normal”, “infiltrated” or “cancer”. This allowed the generation of a dataset with 161 
spectral measurements with a histopathological oncological assessment as ground truth. Typical 
spectra for each class as well as a corresponding histopathology slide are presented in the following 
figure.  
 
Figure 2.4  (Top) Histopathology images of 3 brain tissue biopsy samples (left: dense cancer 
tissue, middle: invasive cancer, right: normal tissue) corresponding to locations where RS 
measurements were made. (Bottom) Raman spectra of the measurement locations showing 
spectral differences. (Figure reproduced from Jermyn et al. 2015) 
Machine learning algorithms (gradient boosted trees) were used with k-fold (10 folds) cross 
validation on the dataset and yielded a diagnostic accuracy of 92%, with 93% sensitivity and 91% 
specificity. Using a handheld probe with the same design, Aubertin et al. performed ex vivo 
research on human prostate. They reported detection of prostate cancer in freshly harvested, 
unprocessed ex vivo slices of human prostate following radical prostatectomy. Raman spectra were 
collected all over the surface of the prostate slices immediately following surgery and each point 
where data was collected was marked with ink. The prostate slices were then sent for 
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histopathological assessment and each spectrum was matched to a pathologist’s diagnosis. A 
dataset of 925 spectra (149 cancerous, 776 benign) was obtained from 32 prostates and RS was 
able to distinguish prostatic from extra prostatic tissue and benign from malignant tissue with 
sensitivities of 82%, 83%, 86% and 87% respectively[37]. Figure 2.6 summarizes the process of 
histopathology registration and shows mean spectra collected for benign and cancerous classes.  
 
Figure 2.5 (left) Methodology for spatial correlation of Raman spectroscopy measurements and 
tissue for diagnosis. Prostate specimen is divided into four quadrants to demonstrate each stage of 
the methodology performed on the same prostate slice (figure on from Aubertin et al. In 
preparation). (right) Average spectra of 149 spectra from cancerous tissue in red and 776 spectra 
from normal tissue in green (original figure) 
 Previous work thus shows successful in vitro and ex vivo prostate tissue characterization 
which show promise to address unmet clinical needs in RA-RP.   RS probes have also successfully 
been used in vivo on multiple organs with promising results. To our knowledge, this technique has 
not been applied in vivo on prostate yet. 
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CHAPTER 3 METHODS & RESULTS COMPLEMENTARY TO THE 
RESEARCH ARTICLE  
The following chapter describes the scientific approach employed to achieve the objectives set out 
in this work. A general overview of the methods employed for the realization of the objectives set 
out in section 1.3 is presented.  
3.1 Objective 1 : Integration of RS to the da Vinci surgical robotics 
platform 
The first objective set out in thesis was the design and development of an RS system, using two 
excitation wavelengths, adapted for integration to a surgical robotics platform. The system is based 
on previous systems used by our research team with important modifications outlined in the 
sections below. First, a general overview of the system is presented followed by each of its 
components, the work done in assembling them, and the primary hurdles overcome.  
3.1.1 Raman spectroscopy system  
An RS system adapted for robotic integration was designed and assembled. The system is primarily 
composed of a spectrometer coupled to a highly sensitive CCD camera, a laser excitation source 
capable of delivering light at two excitation wavelengths and a fiber optic probe responsible for 
light delivery and collection. A custom acquisition software coordinates all spectral acquisitions, 
communicates with system components to set parameters and handles data exchange/storage. The 
following figure shows the assembled RS system as well as a schematic representation of the  
connections between its components :  
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Figure 3.1 : (top) Picture of the assembled RS system with laser, computer running acquisition 
software and spectrometer. (bottom) Schematic overview of the Raman spectroscopy system 
components and the connections between them. Blue arrows represent digital/electrical 
connections while orange ones represent optical/fibered connections.   
 
3.1.1.1 Spectrometer & Camera 
A custom spectrometer built by EMVision LLC was ordered for this project.. The spectrometer is 
optimised for collection in the 800-900 nm range where it has a resolution of ~0.15 nm. This 
corresponds to the FP region (500-2000 cm-1) of a 785 nm excitation and the HWN region (2500-
4000 cm-1) of a 680 nm excitation. Light travels from the RS probe’s collection optics through  a 
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150 um slit where it is then diffracted onto the CCD array of a highly sensitive detector (Andor 
Newton 920 XT). The camera parameters used for all spectral acquisitions in this project were set 
based on recommendations from colleagues and the industrial partner ODS Medical and are listed 
in the table below :  
Table 3.1 : Acquisition parameters used for the Andor Newton camera  
Parameter Value 
Detector temperature -80 
Exposure time 75-100 mS 
Vertical shift speed 1.8 us 
Horizontal shift speed 2.5 MHz 
Gain 2x 
Image mode Full vertical binning 
Acquisition mode Kinetic series 
Baseline clamp ‘on’ 
 
The spectrometer was manufactured by Emvision LLC and built to spec for this project. It is worth 
noting that initial tests with the spectrometer showed signs of stray light on spectra. This was solved 
by inserting dark absorbing material on the inner walls of the spectrometer to block unwanted 
reflections in the system.   
 
3.1.1.2 Raman probe adapted for robotic use 
Current Raman probes for in vivo use have been designed for handheld use and are too large for 
robotic integration. As such, a Raman probe was designed for this purpose. From an optics 
standpoint, the probe has a similar design to the one currently used by industrial partner ODS 
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Medical for its ongoing clinical trial in humans. The probe consists of a central excitation optical 
fiber surrounded by 12 collection optical fibers. A bandpass filter on the excitation lens narrows 
the excitation spectrum while a notch shaped longpass covering only the collection fibers lets 
through wavelengths in the range of the Raman spectra being measured while filtering out 
contributions from dominant Rayleigh scattering.  The distal lens at the tip of the probe sends the 
central excitation straight through while focusing captured light back into the collection fibers.  
From a mechanical standpoint, the outside of the probe casing was designed to be grasped by 
robotic instruments. It is a 2.5 mm wide and 6.5 mm long cylinder with its side walls flattened in 
a hexagonal pattern. The parallel flat faces are picked up by standard robotic graspers manufactured 
by Intuitive (be it a standard needle driver robotic arm or a Prograsp instrument). The following 
figure shows a close up view of the probe, a blown up view with all its components and a to scale 
comparison of the current design with the handheld probe used by ODS Medical and in previous 
studies. 
 
Figure 3.2 : (left) Side-by-side and to scale comparison of the probe designed for robotic integration 
and the handheld one currently used for surgical interventions by our group and the industrial 
partner ODS Medical. (right)  close-up view of the hexagonal profile machined on the probe tip to 
facilitate grasping using standard robotic equipment and a blown-up view of the main optical 
elements of the probe 
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The distal end of the probe extends into 1.5 m of optical fibres which connect the excitation fiber 
to the excitation source with an FC/PC connector and the 12 collection fibers to the spectrometer 
through an MTP connector. The probe and its coating are sterilisable through standard STERRAD 
procedures.  
3.1.1.3 Laser & laser controller 
The laser used for Raman acquisitions is equipped with both a 680 nm and a 785 nm diode coupled 
to a single FC/PC connector. Synchronising laser excitation and spectral acquisition required the 
development of a board capable of communicating with the laser (to control power and wavelength 
selection), the spectral acquisition software (to determine which power and wavelength to deploy) 
and the camera (to ensure synchronisation). The controller was developed using an Arduino Uno, 
an Analog Shield (Agilent electronics) and a custom shield to make all necessary electrical 
connections. It consists essentially of a high precision 10 bit DAC which is used to control laser 
power and a TTL switch which toggles between wavelengths. Laser activation is controlled by 
monitoring the “FIRE” pin on the Andor Newton camera. The master software sets the wavelength 
on the laser controller, which then monitors the fire pin for a rising edge. The laser is turned on 
immediately (within 1 ms of a rising edge) after camera fire and is turned off immediately on a 
descending edge (within 1 ms of a descending edge) of the camera fire. For safety, a watchdog 
timer is implemented on the controller to turn off the laser automatically after 500 ms in the event 
that the fire pin sequence does not function properly. 
  
Figure 3.3 (left) Laser & laser controller (right) side view of laser controller with rear connections 
to laser unit.  
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3.1.1.4 Software GUI  for data acquisition 
 
Figure 3.4 : Screenshot of the acquisition software used to perform all spectral measurements 
A software GUI is necessary to orchestrate spectral acquisitions, communicate between different 
system components and store information related to each measurement. The software used for this 
project is a modified version of ODS Medical’s software currently used to acquire Raman spectra 
with one wavelength. The software (written in C++ using Qt) was heavily adapted for this project. 
First and foremost, the software was modified to accommodate two excitation wavelengths and 
interface with a new laser controller. Software was written to calibrate power for both wavelengths, 
set excitation power, exposure time, and number of spectra independently. Acquisition parameters 
are communicated to an Arduino based laser controller (section 3.1.1.3) which then interfaces with 
the laser and camera to perform acquisitions. An automatic power control (APC) algorithm was 
developed to automatically determines optimal laser power for each laser to occupy the most 
dynamical range of the CCD detector. When enabled, the APC algorithm performs two single 
acquisitions per wavelength on the sample prior to performing the full one. Since the relationship 
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between signal intensity and laser power used is linear, the software uses the dynamical range 
occupied at each of these two powers to do a linear interpolation of optimal power for each 
wavelength. In addition to incorporating two wavelengths, the software was modified to allow 
external platforms to easily perform spectral acquisitions. A TCP/IP server was written which 
allows clients to simply connect to a specified IP and port to communicate. Optional parameters 
allow to set specific parameters and send information to identify/landmark acquisitions.  The 
following figure illustrates the simplicity of connecting to the platform with two code snippets (one 
in matlab, one in python) showing all code required to initiate an acquisition.  
 
function response = ODSCommunicate(ip, port,i) 
  
t = tcpip(ip, port, 'Timeout', 3); 
fopen(t); 
fwrite(t,'go');  
fwrite(t,num2str(i));  
  
start = clock; 
Timeout = 2;  
  
response = fread(t,1); 
while (isempty(response) || response ~=100 ) 
   response = fread(t,1);  
    
end 
response = char(response);  
  
end 
 
 
import socket 
 
# Server adress and communication parameters 
TCP_IP = '169.254.113.23' 
#TCP_IP = '127.0.0.1' 
TCP_PORT = 50382 
BUFFER_SIZE = 1024 
 
# Info to send to server 
MESSAGE = "go" 
ID = "123" # a string used to describe the measure (the ID will be saved to 
file with each acquisition) 
 
# conncetion to the server and data exchange 
s = socket.socket(socket.AF_INET, socket.SOCK_STREAM) 
s.connect((TCP_IP, TCP_PORT)) 
s.send(MESSAGE) 
s.send(ID) 
 
#the server will return a 'RCCC' string after a succesful acquisition where :  
# R is the classifer result (0 - no classification, 1 - class 1 , 2 - class 2 
(classifier dependant) ) 
# CCC is a number between 0 and 100 representing classifier confidence 
data = s.recv(BUFFER_SIZE) 
print(data) 
 
 
 
Figure 3.5 : examples of TCP/IP protocol required to communicate with the RS platform via a 
specified IP/Port in Matlab (left) and Python (right) 
3.1.1.5 Raman shift (x axis) and relative intensity (y axis) calibration 
X-axis and relative intensity correction are performed using molecular standards (acetaminophen 
& NIST 2241 respectively). X-axis to pixel correspondence is obtained using a 785 nm fingerprint 
Raman spectrum of Tylenol. Peaks from the spectrum obtained by the system are compared to 
reference peak positions (using a purpose built GUI shown in the following figure) and a 
polynomial fit is used to compute the x-axis to pixel correspondence of the measured spectrum.  
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Figure 3.6 : software used to compute x-axis to pixel correspondence of the spectrometer. Peaks 
from a measured Tylenol spectrum are matched to their corresponding peaks on a reference 
spectrum one by one. 
The following figure shows the measured spectrum plotted against it’s calibrated x-axis with an 
overlay of the reference spectrum showing proper peak alignment.  
 
Figure 3.7 : calibrated measured spectrum overlayed with reference spectrum showing proper 
peak alignment 
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This technique is not suitable for the high-wavenumber (680 nm excitation) spectrum because of a 
relatively low peak count. As such, x-axis calibration for high-wavenumber spectra is calculated 
using the precise excitation wavelengths (within 0.15 nm) provided by the laser manufacturer. The 
calibrated x-axis is converted from wavenumbers to corresponding nm and back using precisely 
known excitation wavelengths and the following equation. 
∆𝑤 = (
1
𝜆0
− 
1
𝜆1
) |
𝜆0𝑖𝑠 𝑡ℎ𝑒 𝑒𝑥𝑐𝑖𝑡𝑎𝑡𝑖𝑜𝑛 𝑤𝑎𝑣𝑒𝑙𝑒𝑛𝑔𝑡ℎ (𝑛𝑚)
𝜆1𝑖𝑠 𝑡ℎ𝑒 𝑠𝑝𝑒𝑐𝑡𝑟𝑢𝑚 𝑤𝑎𝑣𝑒𝑙𝑒𝑛𝑔𝑡ℎ (𝑛𝑚
∆𝑤 𝑖𝑠 𝑡ℎ𝑒 𝑅𝑎𝑚𝑎𝑛 𝑠ℎ𝑖𝑓𝑡 (𝑐𝑚−1)
 
Relative intensity (y-axis) correction is obtained using a NIST 2241 relative intensity correction 
fluorescence standard. The standard is provided with a certified polynomial for the theoretical  
spectrum( 𝐼𝑆𝑅𝑀(∆𝑤) ) of the standard which relates the relative spectral intensity to the Raman 
shift. Dividing the theoretical curve by a measured spectrum of the standard (𝑆𝑆𝑅𝑀(∆𝑤)) can be 
used to determine a spectral intensity-response correction (𝐼𝑐𝑜𝑟𝑟(∆𝑤)) unique to the Raman 
system[19]. This correction curve can then be used to obtain Raman spectra (𝑆𝑐𝑜𝑟𝑟(∆𝑤)) that are 
corrected for a number of, but not all, instrument-dependent artifacts[19] through simple element 
to element multiplication. The following equations summarize the process of relative intensity 
correction applied to each processed spectrum.  
𝐼𝑆𝑅𝑀(∆𝑤) = 𝐴0 + 𝐴1 ∗ (∆𝑤)
1 + ⋯ + 𝐴5 ∗ (∆𝑤)
5 |
𝐴𝑛 𝑎𝑟𝑒 𝑐𝑒𝑟𝑡𝑖𝑓𝑖𝑒𝑑 𝑝𝑜𝑙𝑦𝑛𝑜𝑚𝑖𝑎𝑙 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡𝑠
∆𝑤 𝑖𝑠  𝑅𝑎𝑚𝑎𝑛 𝑠ℎ𝑖𝑓𝑡 (𝑐𝑚−1)
 
𝐼𝑐𝑜𝑟𝑟(∆𝑤) =  
𝐼𝑆𝑅𝑀(∆𝑤)
𝑆𝑆𝑅𝑀(∆𝑤)
 
𝑆𝑐𝑜𝑟𝑟(∆𝑤) =  𝑆𝑐𝑜𝑟𝑟(∆𝑤) ∗ 𝐼𝑐𝑜𝑟𝑟(∆𝑤) 
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3.1.2 Clinical integration & workflow  
 
The modified probe is designed to be inserted to the patient using a “drop in” approach. The Raman 
probe is inserted to the patient through a laparoscopic port. This can either be the port used for the 
camera endoscope or a laparoscopic assistant port. Assistant ports are insertions commonly used 
in RA-RP surgery which are placed 5-10 cm away from robotic arm ports for surgical assistants to 
insert classic laparoscopic instruments during the surgery. Trocards span these ports and commonly 
have diameters between 8-12 mm leaving 5.5 – 10.5 mm of clearance for the probe fiber to move 
when being manipulated. When the surgeon is ready to use the RS probe, the laparoscopic assistant 
removes it from its sterile packaging and feeds it through the chosen port. Once the probe is inserted 
to the patient, the surgeon uses may use his instruments to grasp it and prepare for RS 
measurements. The following figure shows a CAD rendered view of the proposed approach. 
 
23 
 
 
 
Figure 3.8 :  3D rendered representation of integration to the patient. The probe is inserted 
through an accessory or camera port and manipulated by a standard da Vinci laparoscopic 
instrument to reach the target anatomy (red) 
Once the probe is inserted to the patient and picked up by a da Vinci arm, the surgeon and clinical 
staff coordinate with the RS system operator to perform acquisitions as follows :  
1. The surgeon/operator places the probe on the area to be interrogated.  
2. The surgeon gives an audible cue to perform the acquisition. 
3. The Raman operator performs an acquisition and gives an audible cue when it is done. 
4. The surgeon/operator communicates landmarking information to the RS system operator 
who logs it in the software with the corresponding measurement.  
 
3.1.3 System validation  
 
System validation was performed using a custom made 3d-printed phantom filled with identical 
silicone insertions. The RS system coupled to a da Vinci robot manipulated by a trained surgeon 
was used to perform spectral acquisitions on each of the insertions putting the probe at various 
angles and spectra were compared for repeatability. More details and results on this process are 
presented in section 4 of this thesis. 
Complementary to the phantom evaluation, light contributions from the da Vinci robot’s LED 
based endoscopic illuminator were measured using the spectrometer to assess whether they would 
have an impact on spectral measurements taken in vivo. The following figure shows background 
spectra (laser powered off) acquired with both the illuminator ‘on’ and ‘off’.  
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Figure 3.9 : light contribution of the da vinci illuminator on a  background measurement when 
'on' and 'of' 
Both ‘on’ and ‘off’ background spectra show no sharp peaks and very weak intensities when 
compared to the signal of interest : they occupy roughly 300/62000 CCD counts while the raw 
Raman/fluorescence signal occupies ~20-60000/60000 CCD counts. Based on these findings the 
illuminator was kept ‘on’ during in vivo  measurements described in section 3.2.2. 
3.2 Objective 2: Collect ex vivo and in vivo Raman spectra from 
human prostate and peri prostatic organs/tissues  
Gathering a large dataset is an essential requirement to assessing the potential of RS to perform 
prostate tissue characterization. Due to the difficulties associated with gathering in vivo spectra, a 
larger ex vivo dataset was first acquired to assess classification potential. In vivo data was then 
acquired on 5  patients as a first step towards gathering a comparable dataset and a proof of concept 
of the feasibility of performing RS in vivo during RARP.  
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All components of this study were approved by the institutional ethics Review Board (CHUM 
Research Center, Montreal, Canada, REB #17.149), and all methods were performed in accordance 
with the relevant guidelines and regulations.  
 
3.2.1 Collect Raman spectra from whole prostates following RP  
RS measurements were performed on the surface of whole, unprocessed, freshly excised human 
prostates immediately following RP on 20 patients. To perform these measurements, the RS system 
was placed on a mobile cart which was brought directly to the operating theatre at the end of RA-
RP procedures. Measurements were performed in a light-tight box equipped with an articulated 
arm used to secure the probe during measurements as depicted in the following figure :  
 
Figure 3.10 :  inside the light-tight box used to perform RS acquistions ex vivo at the end of RA-
RP 
For measurements, the prostate was visually segmented into gross anatomical regions and ~5 
spectra per prostate were acquired at each of the following: 
1. The apex region 
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2. The base region  
3. The posterior region 
4. The left lateral lobe  
5. The right lateral lobes 
Spectra were also collected on the following extra-prostatic structures when sufficient tissue was 
present following RP :  
1. The seminal vesicles  
2. The vas deferens canals 
Each RS acquisition consists of a fingerprint (785 nm excitation) and a high wavenumber (680 nm 
excitation) taken sequentially with  the acquisition parameters listed in table 3.2. 
Table 3.2 : Range of acquisition parameters used throughout the ex vivo and in vivo experiments  
 
Spectra were acquired collected across patients and anatomical origin will be compared to assess 
the feasibility of using RS as a tool to characterize prostate tissue and distinguish prostatic from 
extra prostatic tissue/organs. Details on the amount of spectra collected from each region and 
number of patients can be found in chapter 4 of this thesis.  
Excitation 
wavelength (nm) 
Spectral 
range (cm-1) 
Exposure time 
(mS) 
Delivered power 
(mW) 
# of spectra 
per 
acquisition Camera gain 
680 500-2000 100 0-150 10-15 2X 
785 2500-4000 100 0 -150 10-15 2X 
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3.2.2 In vivo data collection during robotic-assisted radical 
prostatectomy procedures 
The system presented above was used during RARP to collect data from 5 human prostates in vivo. 
Data was collected in the same anatomical regions of the prostate as the ex vivo portion o the 
sreseach  
Table 3.3 : Distribution of in vivo Raman spectra acquired in surgical cavity during radical 
prostatectomy procedures.  
 
Anatomical region Sub-region N samples 
Anterior   7 
 Apex 1 
 Base 6 
Extra-prostatic  13 
 Neurovascular 
Bundle 
5 
 Seminal vesicles 
Bladder 
3 
5 
Total  20 
3.2.3 Process automation for cancer detection (automated platform)  
A complementary portion of this work consisted of working on the automation of data acquisition 
for prostate cancer research developed by Aubertin et al. Aubertin’s method (results available in 
literature review) consists of acquiring Raman spectra on a cross section of prostate harvested 
immediately following RP. Roughly 50 spectra are acquired on a ~ 1 cm cross section of prostate 
and each point interrogated is manually labelled with a dot of ink. The prostate slice is then sent 
for histo-pathological analysis which provides a diagnosis for each of the labelled spots of ink. 
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Figure 3.11 : current process for performing Raman measurements on a prostate slice and obtaining 
registration from histopathology.  
Useful machine learning based application of these datasets require large amounts of data. While 
this process works, it is both lengthy and labor intensive. As such, through supervision of and 
collaboration with a group of 4th year engineering students at Polytechnique Montreal this process 
was fully automated.  
Automation was achieved by modifying a readily available and open source 3D printer to 
accommodate a Raman probe. The platform is equipped with a bird’s eye view camera which 
provides an overhead view of the measuring base. A graphical interface (coded in Matlab) allows 
the user to select points to be interrogated on the specimen graphically. Once all points are selected, 
the platform begins acquiring spectra by repeating the following sequence :  
1. The probe is placed n cm (user configurable) above the platform.  
2. The probe is displaced above the point selected in the XY plane.  
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3. The probe descends ~0.5 mm at a time until contact with the point selected is achieved. 
Contact is detected by monitoring a modified digital kitchen scale placed below the sample.  
4. The platform communicates with the ODS Raman acquisition software and an acquisition 
is performed. An acquisition ID is sent to the ODS software which is logged with the 
spectral data.  
5. The probe is lifted n cm and once again communicates with the ODS software. A low power 
acquisition is performed to assess whether the probe tip needs to be cleaned.  
6. Steps 1-4 are repeated until all points selected by the user have been interrogated  
  
Figure 3.12 : (left) Conceptual view of automated platform. (center) Complete working version of 
automated Raman platform. (right) mask generated from platform camera image for registration 
with histopathology 
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Platform positioning accuracy was validated to be <1 mm by substituting the probe with a marker 
and selecting points on a sheet of millimetric paper  
Figure 3.13 : Evaluating platform precision : a marker was mounted on the platform instead of the 
Raman probe. Points were selected on milimetric paper using the platform software and distance 
between point selected and point inked was measured 
3.3 Objective 3: Classification/tissue characterization based on 
acquired datasets 
3.3.1 Objective 3.1 : Train algorithms capable of differentiating prostatic 
from peri-prostatic tissue 
Spectra originating from the prostate (apex, base, lateral lobes, anterior face) were grouped together 
and labelled as ‘prostate’ spectra while spectra collected on surrounding anatomy (vas deferens, 
seminal vesicles) were labelled ‘extra prostatic’ based on clinical utility defined by a urologist and 
31 
 
 
 
pathologist collaborating on the project. The Matlab classification toolbox was then used to test a 
variety of different classifiers and assess their performance on the dataset. Among these were 
LDAs,, regular SVMs and SVMs with quadratic or cubic kernels. A holdout validation approach 
was used where 75% of the initial dataset is used as a training set while 25% is set aside to assess 
performance of the trained classifier. Most classifiers performed reasonably on the dataset though 
quadratic/cubic SVMs returned the best performance. The following figure illustrates the workflow 
in assessing classification performance while results are presented in chapter 4 of this thesis.  
 
Figure 3.14 : Classification workflow used for characterizing prostate vs extra-prostatic tissue.  
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CHAPTER 4 ARTICLE 1 : INTEGRATION OF A RAMAN 
SPECTROSCOPY SYSTEM TO A ROBOTIC-ASSISTED SURGICAL 
SYSTEM FOR REAL TIME TISSUE CHARACTERIZATION DURING 
RADICAL PROSTATECTOMY PROCEDURES 
The work outlined above set the stage for a peer reviewed publication in the Journal of Biomedical 
Optics which is currently submitted and awaiting peer review. The following chapter presents this 
article as it was published. The publication is titled “Integration of a Raman spectroscopy system 
to a robotic-assisted surgical system for real time tissue characterization during radical 
prostatectomy procedures’ and its authors are the following :  
Michael Pintoa,b, Kevin C. Zornb, Jean-Philippe Tremblaya, Joannie Desrochesa,b, Kelly Aubertina,b, 
Eric Marpled, Chris Kentc, Frederic Leblond*a,b, Dominique Trudel*b, Frederic Lesage*a,e 
aPolytechnique Montreal, CP 6079, Montreal, Canada, H3C3A7 
bCentre de Recherche du Centre Hospitalier de l’Université de Montréal, 900 rue Saint-Denis, Montreal, Canada, H2X0A9 
cODS Medical, 5155 Avenue Decelles, Montreal, Canada, H3T2B2 
 dEmVision LLC, 1471 F Road, Loxahatchee, U.S.A, 33470 
eCentre de Recherche de l’Institut de Cardiologie de Montréal, 5000 Bélanger Est, Montréal, Canada, H1T 1C8 
*these authors contributed equally to this work 
4.1 Abstract 
Surgical excision of the whole prostate through a radical prostatectomy (RP) procedure is part of 
the standard of care for prostate cancer. Positive surgical margins (cancer cells having spread into 
surrounding non-resected tissue) occur in as many as 1 in 5 cases and strongly correlate with 
disease recurrence and the requirement of adjuvant treatment. Margin assessment is currently only 
performed by pathologists hours to days following surgery and the integration of a real-time 
surgical readout would benefit current prostatectomy procedures. Raman spectroscopy (RS) is a 
promising technology to assess surgical margins: its in vivo use during RP could help insure the 
extent of resected prostate and cancerous tissue is maximized. In this work, we thus present the 
design and development of a dual excitation RS system (680 nm and 785 nm excitations) integrated 
to the robotic da Vinci surgical platform for in vivo use. Following validation in phantoms, 
spectroscopic data from 20 whole human prostates immediately following RP was obtained using 
the system. With this dataset, we were able to distinguish prostate from extra prostatic tissue with 
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an accuracy, sensitivity, and specificity of 91%, 90.5%, and 96% respectively. Finally, the 
integrated RS system was used to collect preliminary spectroscopic data at the surgical margin in 
vivo in 4 patients.   
Keywords: Raman spectroscopy, prostate cancer, robotic surgery. 
4.2 Introduction 
Prostate cancer is the second most frequently diagnosed cancer world-wide[1]. In the United States, 
in 2015, there were an estimated 220,800 new cases and 27,540 deaths, namely approximately 9% 
of all cancer-related deaths[2]. Surgical excision of the whole prostate through radical 
prostatectomy is an important part of the standard of care for prostate cancer. Recent large surveys 
of the SEER and National Cancer databases show an increase in the use of radical prostatectomy 
to 40-55% of cases while rates of radiotherapy based treatment have decreased for medium and 
high risk patients over the past decade[38], [39]. Radical prostatectomy procedures can be 
performed either using open or minimally invasive techniques (classic laparoscopy or robotic-
assisted surgical methods). Minimally invasive techniques have comparable clinical outcomes, 
however robotic-assisted prostatectomy procedures lead to shorter hospital stays, less blood loss 
and reduced complication rates[3]. Furthermore, robotic surgery provides magnified, stereoscopic, 
high definition visualization, a wide range of motion (7 degrees of freedom), elimination of tremor, 
and surgeon comfort at a seated console[40]. Adoption of robotic surgery systems has also been 
rising over the last decade: a retrospective study of more than 500,000 prostatectomies performed 
in the U.S. found adoption rates for robotic surgery leaping from 0.7% in 2003 to 42% in 2010[41].  
 The clinical objective of a radical prostatectomy procedure is the complete removal of the 
organ while sparing nerves and other surrounding tissues. Removing the entirety of the prostate is 
made difficult by the lack of a clear histologic capsule which often results, in part due to limitations 
of current tissue imaging techniques, in prostate tissue being left in the surgical cavity after the 
procedure in as many as 29% of cases[4]. This is an important clinical problem often leading to 
biochemical recurrences, namely a rise in the blood level of prostate-specific antigen (PSA) in 
prostate cancer patients after the surgical treatment, which may misleadingly be interpreted as 
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disease recurrence. However, none of the currently available technologies to identify cancerous 
tissue (including histopathology, computed tomography (CT), magnetic resonance imaging (MRI), 
positron emission tomography (PET) scans and ultrasound) can be used reliably during surgery.  
 Raman spectroscopy is an emerging technology that has shown promising results for highly 
sensitive and specific molecular tissue characterization[7], [8], [15]. It is based on the detection of 
inelastically scattered light following tissue excitation with near-infrared light. The resulting 
spectral shifts are associated with molecular vibrations and provide an avenue for precise and 
quantitative fingerprinting since different molecular species have their own spectral signature. 
Raman spectroscopy has previously been shown by our group to detect glioma in vivo during 
surgery by successfully differentiating normal brain from cancer tissue in 17 patients with grade 2-
4 gliomas with a sensitivity of 93% and a specificity of 91%[10]. More recently, a multimodal 
(fluorescence spectroscopy, diffuse reflectance spectroscopy, Raman spectroscopy) optical cancer 
detection system was used to show that brain, lung, colon, and skin cancers could be detected in 
situ during surgery with an accuracy, sensitivity, and specificity of 97%, 100%, and 93%, 
respectively[42].  Raman spectroscopy has also very recently been integrated to a commercial 
biopsy needle for in vivo targeted brain cancer tissue biopsies[43]. More specific to prostate cancer, 
in a study involving 32 fresh and non-processed human prostate specimens obtained immediately 
following radical prostatectomy, Raman spectroscopy distinguished prostatic from extra prostatic 
tissue with sensitivity/specificity of 82%/83%, and benign from malignant tissue with 
sensitivity/specificity of 87%/86%[37]. Other works have also demonstrated the utility of Raman 
spectroscopy for prostate cancer detection:  It has been shown to identify cancer cells with high 
accuracy in vitro in a study where 4 different cell lines varying from benign prostate cells to prostate 
adenocarcinoma were identified with a sensitivity and a specificity of 96-100% and 99-100%, 
respectively[29]. Using 38 prostate samples, classification algorithms trained on 197 Raman 
spectra were shown to distinguish benign prostate, hyperplasia and inflammation from prostate 
cancer with an accuracy of 86%[34]. In a study involving 27 patients, prostate cancer could be 
classified into Gleason scores (GS) <7, =7 and >7 with an accuracy of 89%[28].  
 Previous Raman spectroscopy work shows promise to leverage the molecular specificity of 
the method to distinguish both benign and cancerous prostatic tissue from surrounding 
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organs/structures which in turn could improve outcomes of radical prostatectomy. Robotic-assisted 
surgical systems provide an ideal platform for the integration and clinical translation of Raman 
spectroscopy. As such, this work demonstrates the design, engineering and successful integration 
of a Raman spectroscopy system to a surgical robotics platform, its validation on a phantom, as 
well as preliminary ex vivo and in vivo spectroscopic data and associated classification results.   
4.3 Methods 
4.3.1 Raman Spectroscopy System 
4.3.1.1 System Overview  
The Raman spectroscopy system is composed of a dual-wavelength laser source, a purpose-built 
spectrometer (Emvision LLC, Loxahatchee, FL, USA), a high-resolution CCD camera (Andor 
Newton 920) and a custom probe (Emvision LLC) adapted for laparoscopic use. The dual-
wavelength laser (Innovative Photonics Solutions, model # 0811A100-B Fat Boy) provides 
interchangeable 680 nm and 785 nm excitation to the optical probe through a single optical fiber 
(0.22 NA, FC/PC connector, 105 m diameter core). The spectrometer was designed to capture 
both the fingerprint (785 nm excitation) and high wavenumber (680 nm excitation) Raman spectra 
through the same slit (width: 150 m) and grating. Table 1 summarizes the physical properties of 
the spectrometer for each spectral region.  
 
Table 4.1 : Principal technical specification of the Raman spectroscopy system. 
 
Excitation 
wavelength (nm) 
Spectral range 
(cm-1) 
Interrogated area 
diameter (mm) 
Delivered power 
(mW) 
Spectral resolution 
(nm) 
680 2500-4000 0.5 0-150 0.1-0.2 
785 500-2000 0.5 0 -150 0.1-0.2 
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 The custom-built probe is a re-design of an instrument developed by our group for work on 
in vivo human brain studies[10]. Briefly, lenses and filters disposed at the distal end of the probe 
allow for collection of the spectroscopic signal from which the Raman contribution can be isolated 
using optical fibers:  a single central fiber for tissue excitation and 12 concentric fibers for detection 
(Figure 1). A band-pass 785 nm interference filter is placed in front of the excitation fiber for laser 
line clean-up and a donut-shaped long-pass filter used in front of the collection to reduce the impact 
of Rayleigh scattered light in the detection path. The filters also eliminate the silica Raman signal 
created from the optical fibers. Other than the fact both high wavenumber and fingerprint detection 
can be achieved with the system, the main difference with respect to our neurosurgery instrument 
is that the outer casing of the new probe was designed to facilitate robotic grasping. It consists of 
a 12 mm long stainless steel cylinder with a 2.5 mm (2.3 hex flat to hex flat ) outer diameter. The 
central portion of the outer casing is machined to have a hexagonal cross section such that all 
opposing faces of the outer portion are flat and parallel making easy to be clamped by a standard 
grasping instrument such as a needle driver or a ProGrasp (Intuitive Surgical #470093) forceps. 
The probe is connected to the Raman spectroscopy system through a 3 m-long fiber optics cable 
wrapped in a housing flexible enough to allow for the probe to be inserted into the surgical cavity 
and manipulated by the robotic-assisted surgical system. 
 Spectroscopic data acquisition (CCD detection triggered and precisely timed with laser 
activation) was coordinated using software written in C++ and Qt. From a high level, the software 
allows the system operator to perform calibration (see section 2.1.2), set acquisition parameters 
(laser power, imaging time, camera gain, number of repeat measurements), perform acquisitions, 
and view results (both raw and processed spectra) in real time. The software also allows for 
automatic calculation of optimal laser power for each wavelength to occupy maximum dynamic 
range of the camera by performing low power acquisistions with each wavelength and 
extrapolating optimal power. Laser power calibration is performed using this software and a 
powermeter (PM1000D, Thorlabs) prior to each use.  
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Figure 4.1 : Visual representation of the Raman spectroscopy system designed and built for 
integration in a robotic-assisted surgical system. Depicted is a close-up view of the hexagonal 
profile machined on the probe tip to facilitate grasping using standard robotic equipment. A blown 
up view of the main optical elements making up the probe is shown as well as a schematic 
representation of the coincident excitation and detection light cones. 
4.3.1.2 Spectral pre-processing 
Several processing steps were applied to each acquired raw spectrum to isolate the vibrational 
spectroscopy contribution from background light (e.g. ambient light, intrinsic tissue fluorescence) 
and system response function. Each acquisition consisted in 10-15 consecutive spectra that were 
averaged together and from which a dark noise measurement (spectrum acquired with laser off) 
was subtracted to correct for dark noise and ambient light contributions. Spectra were then scaled 
for relative intensity changes using a NIST 2241 SRM standard[44] lending Raman spectra 
corrected for the instrument response[19]. Remaining background contributions, including intrinsic 
tissue fluorescence, were then removed using an automated subtraction algorithm developed by 
Zhao et al.[13], [17]. The spectra were then smoothed with a Savitsky-Golay filter (of order 3 and 
with a frame size of 15) and normalized using standard normal variate (SNV) normalization. The 
calibration of the x-axis of the fingerprint spectra was performed by direct comparison with 
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acetaminophen peaks from the literature[45]. Briefly, peaks on an acetaminophen spectrum 
measured with the system are manually identified and a second-degree polynomial fit is calculated 
between measured and literature peaks to generate a calibrated x-axis for the system. For the high 
wavenumber region, the calibrated x-axis in wavenumbers for the fingerprint region was converted 
to nanometers using the known 785 nm excitation wavelength and back to Raman shifts using the 
known 680 excitation wavelengths (precise excitation wavelengths within 0.1 nm were provided 
by the laser manufacturer).   
 
Figure 4.2 : Pre-processing steps for a 785 nm fingerprint ex vivo prostate Raman spectrum. (a): 
Raw spectrum after averaging and dark noise subtraction, (b): NIST correction curve shown for 
visualisation of instrument response features. (c): raw spectrum multiplied by the NIST correction 
curve (blue curve) and polynomial fit computed to estimate the fluorescence background 
contribution (orange). (d): Subtraction of the fluorescence background curve from the NIST 
corrected raw spectrum in (c). (e): Savitsky-Golay filtered signal to eliminate high frequency noise. 
(f) : SNV-normalized spectrum.    
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4.3.1.3 Optical probe integration in a robotic-assisted surgical system 
The Raman probe system was integrated with a robotic-assisted surgical system (daVinci Xi, 
Intuitive Surgical) to allow Raman spectroscopy tissue interrogation during radical prostatectomy 
procedures. Integration of the spectroscopy system with the robotic-assisted surgical system 
imposed several constraints on the design, including the fact the probe needed to be inserted into 
the patient through an assistant port which consists of an 8-12 mm trocar placed through the 
patient’s abdomen. Moreover, the mechanical design needed to allow the surgeon to grasp, 
manipulate, and immobilize the probe using a standard robotic grasping instrument. Integration 
also needed to provide enough flexibility to perform measurements at various angles throughout 
the surgical cavity despite a design based on optical fibers with limited bending radii. Figure 3 
provides an overview of the design constraints imposed and how the Raman spectroscopy probe 
was integrated with the robotic platform to allow intraoperative measurements.  
 
 
Figure 4.3 : Representation of the Raman spectroscopy probe integrated with the da Vinci robot-
assisted surgical system composed of four independently controllable robotic arms (3 visible here, 
labeled 1, 2 and 3). The arms have interchangeable instruments and the probe was manufactured 
to be compatible with grasping instruments (such as the Prograsp or needle driving arm 
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manufactured by Intuitive surgical). The grasping arm is shown ceasing the Raman spectroscopy 
probe for intraoperative measurements, with a magnified view provided as an aid to visualization.   
 
 A phantom was fabricated and used in the scope of an experiment to verify that the 
integration of the spectroscopy system with the robot-assisted surgery platform allowed repeatable 
measurements to be achieved over a sufficiently broad range of fiber optics cable curvatures. The 
phantom consisted of a 6.5 cm-diameter (consistent with the size of a diseased human prostate) 
hemisphere with regularly spaced 3 mm-diameter insertions along intersecting arcs on the surface 
(Figure 4a). The insertions were evenly spaced across two perpendicular great circles of the 
hemispheres (11 for each great circle, ~16 between insertions). The phantom was built using a 3d 
printer (Prusa i3) and the insertions were filled using a silicone mixture (GE 100% silicone) with 
clearly distinguishable vibrational spectroscopy features and relatively low fluorescence level. A 
trained robotic surgeon was asked to manipulate the probe and put it in contact with all insertions 
along one of the two arcs without letting go of the probe. A spectroscopy measurement was 
obtained each time contact was made between the probe and an insertion, totalling 11 raw average 
Raman spectra acquired and processed as described in section 2.1.2. This allowed data to be 
acquired for various optical cable bending radii for angles (between the main axis of the probe and 
the base of the phantom) ranging from 0 to 90. 
4.3.2 Data collection on ex vivo human prostates  
This portion of the study was designed to characterize Raman spectra associated with prostatic 
tissue. Spectroscopic data was collected directly on freshly excised whole human prostates 
following radical prostatectomy. The measurements were performed on a mobile cart equipped 
with the Raman spectroscopy platform and a light-tight box ensuring minimum levels of ambient 
light contributions. Using an adjustable arm, the probe was securely placed in contact with freshly 
excised, non-processed prostate tissue at the plane of resection, the doors to the dark box were 
closed, and measurements were performed. Specifically, 10-15 spectra per point were acquired, 
the on-tissue laser power was automatically computed between 0-150 mW using the automated 
power adjustment routine (see section 2.1.1), camera gain was set to 2X and exposure time at 75-
https://www.laparoscopyhospita
l.com/docking-in-robotic-
surgery.html 
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100 ms per spectrum. Measurements were planned according to grossly estimated prostate 
anatomy; for each prostate, spectra were collected on the apex, the base, the left and right lateral 
lobes, the posterior face, the left and, when possible, the right seminal vesicles and the vas deferens 
canals (Figure 5). The ex vivo study was approved by the institutional ethics Review Board (CHUM 
Research Center, Montreal, Canada, REB #17.149), and all methods were performed in accordance 
with the relevant guidelines and regulations. More details on the data acquisition protocol can be 
found in previous work using Raman spectroscopy for prostate tissue characterization[46]. In total 
599 spectra were acquired from 20 patients (on average 30 spectra per patient) and grouped by 
anatomical regions (Table 2).  
Table 4.2 : Distribution of ex vivo Raman spectra acquired on whole prostates following radical 
prostatectomy procedures. 
 
 Sub-region Number of 
spectra 
Anterior   383 
 Apex 102 
 Base 108 
 Lateral lobes 173 
Posterior  105 
Extra-prostatic  111 
 Vas deferens 41 
 Seminal 
vesicles 
79 
 
Total  599 
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4.3.3 In vivo data collection during robotic-assisted radical 
prostatectomy procedures 
Raman spectra of prostate tissue near the surgeon’s plane of resection around the prostate (at the 
surgical margin) were acquired in vivo using the Raman spectroscopy system in combination with 
a robotic-assisted surgical platform (daVinci Xi, Intuitive Surgical). The in vivo study was 
approved by the institutional ethics Review Board (CHUM Research Center, Montreal, Canada, 
REB #17.149), and all procedures were performed in accordance with the relevant guidelines and 
regulations. Towards the end of the prostatectomy procedure, the probe was inserted into the 
patient’s abdominal cavity and manipulated by the surgeon using a forceps robotic instrument 
(Intuitive Surgical #470093). The surgeon placed the probe on each point of interest by establishing 
visual contact between the probe tip and tissue and applying minimal pressure (Figure 7a). Actions 
were taken to avoid contamination of the Raman spectrum from blood that is not specific to the 
tissue of interest: 1) the surgeon was asked to avoid areas contaminated by blood, 2) a laparoscopic 
assistant was present to suction away any excess blood, 3) increased pressure in the abdomen from 
insufflation (standard for robot-assisted radical prostatectomy procedures[47]) reduced bleeding. 
Before each measurement, the probe was locked into place long enough to allow spectroscopic data 
acquisition using the same procedure as described in section 2.2. Measurement locations were 
chosen by the surgeon to match the gross anatomical regions identified in the ex vivo study and 
were recorded by the Raman system operator. In vivo spectroscopic data was acquired during 4 
robotic-assisted radical prostatectomy procedures for different prostate regions either associated 
with prostatic (anterior region only) or extra-prostatic tissue (Table 3). 
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Table 4.3 : Distribution of in vivo Raman spectra acquired in surgical cavity during radical 
prostatectomy procedures in 4 patients. 
 
Anatomical region Sub-region Number of 
spectra 
Anterior   7 
 Apex 1 
 Base 6 
Extra-prostatic  13 
 Neurovascular 
Bundle 
5 
 Seminal vesicles 
Bladder 
3 
5 
Total  20 
 
4.4 Results 
4.4.1 Integration of the Raman spectroscopy system with the robotic 
assisted surgical platform    
The spectroscopic data acquired for multiple angles on the validation phantom using the Raman 
spectroscopy robotic-assisted surgical system is shown in Figure 4c. The Raman spectra were 
computed by evaluating the mean of the spectra measured on the 11 silicone inserts along a 
hemispheric arc of the phantom. As demonstrated by the small standard deviation (plotted but 
indistinguishable in the figure), minimal variation occurs across all spectra despite increases in the 
bending radius of the optics cable. A histogram of the measurements standard deviation was 
computed to provide a more quantitative representation of the variance (Figure 4d). Measurements 
were acquired across all points on a 180 arc of the phantom without having to let go of the probe 
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and without imposing significant bending/strain on the optical fibers. However, the minimum bend 
radius of the optical fibers is not necessarily a critical consideration with the proposed drop-in 
design. In fact, the thickest fiber in the probe has a minimum bend radius of ~1.5 mm. Bending this 
extreme is easily avoidable with this design for two reasons: slack provided by the 1.5 m of fiber 
allows for larger bend radii and the drop-in design allows for the probe to be picked up at different 
instrument angles.  
 
Figure 4 : (a) Conceptual view of the prostate-simulating phantom used for validation, (b) Raman 
spectroscopy probe manipulated by a surgeon using a robot-assisted surgical system to measure 
the spectrum of silicone inserts, (c) Mean and standard deviation computed from all SNV-
normalized Raman spectra acquired on the silicone inserts with the most prominent Raman peaks 
of the material identified with arrows. Since the variances in (c) are too small to be visualized, (d) 
a histogram of the standard deviation between the spectra acquired at each phantom location across 
all 9 peaks identified is shown in the same units as the processed spectra (e.g. 2 peaks have standard 
deviation between 0 and 0.05)   
(a) 
(c) (d) 
(b) 
Raman 
probe  
Robotic  
Grasper  
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4.4.2 Ex vivo and in vivo Raman spectroscopy in robotic-assisted radical 
prostatectomy procedures  
Figure 5b shows the mean (across all patients) ex vivo Raman spectra for each gross anatomical 
prostate regions that were interrogated. Several of the main peaks and bands usually associated 
with biological tissues are identified with numbers (1-14) in the figure, including the phenylalanine 
peak at 1440 cm-1, the amide III band around 1449 cm-1 as well at the amide III band around 1650 
cm-1. 
 
Figure 5: (a) Prostate regions surveyed using the Raman spectroscopy probe: i - left and right lateral 
lobes. ii - apex. iii - base. iv – posterior. v – seminal vesicles. (b) Mean ex vivo spectra measured 
for each region across 20 patients with prominent Raman bands identified (see Table 4). 
 
 
 
 
 
 
ii
i 
ii 
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(a) (b
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Table 4.4 : Prominent biological tissue Raman bands identified on the ex vivo prostate spectra. 
 
Band 
identifica
tion label 
(see 
Figure 5)  
 
Wavenumb
er 
(cm-1) 
Molecular 
Bond 
Assignment 
Molecular 
Species 
Molecules 
1   854 C-O-C Proteins Tyrosine 
2   950 
 
Proteins Proline, Valine 
3   1004 C-C Proteins Phenylalanine 
4   1078 C-C/C-O Phospholipid
s,,carbohydr
ates 
 
5   1252 NH2 DNA/RNA Guanine, cytosine 
6   1307 CH2 / CH3 Proteins, 
lipids 
collagen 
7   1398 CH2  / C=O Lipids β-carotene 
8   1449 C-H Proteins, 
Lipids 
 
9   1566 CN/NH/COO-
/amide II 
Proteins 
Tyrosine, Tryptophan 
10  1615 C=C Proteins Tyrosine, Tryptophan 
11  1658 Amide I Proteins, 
Lipids, fatty 
acids 
 
12  2879 CH2/CH Lipids, 
proteins 
 
13  2931 CH2 / CH3 Proteins  
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Spectra originating from the prostate (apex, base, lateral lobes, anterior face) were then grouped 
together and labelled as ‘prostate’ spectra while spectra collected on surrounding anatomy (vas 
deferens, seminal vesicles) were labelled ‘extra prostatic’ (Figure 6a). The prominent Raman bands 
were also observed in the ‘extra prostatic’ tissue measurements, with perhaps the most apparent 
differences – when compared with prostate tissue – in and around the amide I band. Analysis was 
then performed to assess the performance of Raman spectroscopy in distinguishing prostate and 
extra prostatic spectra by creating a classification model using support vector machines. The model 
was created using the data associated with the full spectrum (no features selection) and was tested 
on an independent dataset. The later consisted of 25% of all spectra randomly selected across the 
full dataset ensuring no data from the same patient was used in the training phase. Using this model, 
prostate tissue could be distinguished from extra prostatic tissue with an accuracy, sensitivity, and 
specificity of 91%, 90.5% and 96%, respectively. These values were computed from the receiver-
operating-characteristic (ROC) curve shown in Figure 6b that has and area-under-the-curve (AUC) 
of 0.96.  
 
 
Figure 6 : (a) Mean ex vivo Raman spectra for prostate and extra prostatic measurements. (b) ROC 
curve of corresponding classification result obtained using support vector machines. 
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Figure 7b shows the average in vivo Raman spectra associated with all interrogated prostate areas, 
showing that same spectral bands and peaks that were identified in the ex vivo spectra can be seen. 
Figure 7c shows the average in vivo and ex vivo Raman spectra associated with the base prostate 
region. In general, all spectra acquired in vivo express peaks in the same 14 spectral bands as those 
on ex vivo spectra (see Table 4 for peak/molecular identification). Direct visual comparison 
between mean in vivo and ex vivo spectra for the base region of the prostate demonstrate they are 
similar in the fingerprint region based the bands/peaks that are expressed as well as their relative 
intensities. However, the peaks in the high wavenumber region however have noticeably lower 
intensities for in vivo data when compared to ex vivo data.  
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Figure 7 : (a) Close up views of Raman spectroscopy probe during spectral acquisition on 
prostate base in vivo. (b) Mean spectra of specific tissue classes acquired in vivo. (c) Comparison 
of average in vivo and ex vivo spectra for the base prostate region. 
(c) 
(b) 
(a) 
Robotic  
Grasper  
 
RS probe 
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4.5 Discussion  
There is a clinical need in oncology for new technologies to allow accurate and rapid intraoperative 
molecular tissue characterization at the surgical margin during tumor resection interventions. 
Optimal disease management using surgery is critical for prostate cancer patients where positive 
surgical margins occur for as many as 1 in 5 radical prostatectomy cases[5]. Limiting the risk of 
disease recurrence for patients undergoing radical prostatectomy can be achieved by ensuring the 
prostate organ is completely removed and that the disease has not spread beyond the prostatic 
capsule. Ensuring that no prostate tissue is left in the cavity following the procedure can also help 
minimize false positives during post-surgical follow-ups based on PSA, which is secreted by both 
normal and malignant prostate cells. Residual prostatic benign tissue can lead to detectable serum 
PSA which can be falsely interpreted at disease recurrence. The need to limit the resection of and 
damage to normal tissue is also critical in prostate cancer; for example, sparing nerves is critical to 
reduce the risk of erectile dysfunction and preserving continence[6], [48]. However, current 
standard of care technologies used to assist radical prostatectomy procedures are limited in their 
ability to provide detailed point-by-point molecular tissue characterization and thus cannot provide 
surgeons with the information they need to achieve optimal surgical outcome.   
 A growing number of radical prostatectomy procedures are performed worldwide using 
robotic-assisted surgical systems[41]. This rise in robotic-assisted procedures provides a unique 
opportunity for the mechanical integration of new tissue characterisation tools alongside standard 
robotic accessories (e.g. graspers, needle drivers, cauterizers) for routine intraoperative use. These 
new tools could then be used to address the current needs in prostate surgery, namely: i) prostate 
tissue detection, ii) nerve sparring and iii) detection of cancer cells that have invaded beyond the 
confines of the prostate. The use of optical technologies such as Raman spectroscopy can provide 
an avenue for point-by-point molecular tissue characterization and highly accurate classification as 
demonstrated over the last decades by several groups[35], [49]. Given sufficiently large datasets 
(spectra and tissue class labels determined based on histopathology analyses), mathematical 
models can be trained using supervised learning techniques for live tissue classification.   
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 In this work, we have presented the integration of Raman spectroscopy to a robotic-assisted 
surgical system. Specifically, we have presented the initial steps that led to the use of the 
spectroscopy platform for ex vivo tissue characterization as well as a feasibility study 
demonstrating – for the first time – measurements of Raman spectra in vivo at the surgical margin 
during robotic-assisted radical prostatectomy procedures. Validation of the spectroscopy system’s 
ability to acquire spectra at multiple angles compatible with those required for prostate 
measurements was assessed using a custom prostate-simulating phantom. Then, a preliminary 
clinical proof-of-principle study was presented based on ex vivo measurements. Using data 
acquired from 20 prostates (599 spectra in total), a classification model was produced based on 
support vector machines to distinguish prostate from extra prostatic tissue. Using a holdout 
validation dataset (25% of all spectra), the model was able to distinguish between prostatic and 
extra prostatic tissue with an accuracy of 91%, a sensitivity of 90.5% and specificity of 96%.  
 Although those preliminary results are promising, the development of sufficiently general 
models for live and reliable intraoperative tissue characterization will not only require larger 
datasets but also the development of modeling approaches that can perform independently of 
whether the measurements are made under ex vivo or in vivo conditions. As a first step in that 
direction, in this work we have demonstrated the feasibility of acquiring Raman spectra in vivo 
using a robotic-assisted surgical system and demonstrated the validity of the acquired spectra based 
on the detection of expected molecular vibrational modes in biological tissues as assessed by the 
presence of the main tissue bands and peaks (e.g., amide bands, phenylalanine peak). As a 
preliminary demonstration of the consistency between in vivo and ex vivo measurements, in vivo 
and ex vivo spectra from the base region of prostate were compared and demonstrated to be 
compatible in the fingerprint region but significant relative intensity differences in the high 
wavenumber region were observed. Developing a classifier that is valid for clinical use will require 
either the demonstration of interchangeability between the two datasets or collection of enough in 
vivo spectra to train a robust classifier.  
 Robotic integration was sufficient for this proof of concept though many improvements 
remain possible. Firstly, spectral acquisitions were all dependent on the presence of an operator for 
the Raman spectroscopy system. Optimal integration of such a system will instead be controlled 
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by the pedals and switches provided directly to the surgeon through the da Vinci surgeon console 
(as is the case for existing activated instruments such as cauterizing ones). Moreover, the current 
“drop in” design requires the optical probe to be grasped by a separate instrument. Development 
of a custom robotic arm already integrated with the fibers, lenses and filters required for Raman 
spectroscopy will allow for more seamless spectral acquisitions. The integrative work outlined 
above however lays the groundwork for further study into characterization of prostate tissue at the 
surgical margin using Raman spectroscopy and similar optical techniques. Data gathering at a 
larger scale will be a crucial step towards the development of clinically relevant and robust 
algorithms capable of providing surgeons with information regarding tissue make up in real time. 
This technology holds promise for detecting prostate tissue left behind at the margin leading to 
more complete but circumscribed resections, of localizing cancer’s spread when it extends out of 
the prostate and perhaps even of detecting nerves critical for erectile and urinary functions.  
4.6 Conclusion 
There is a strong clinical need for characterization of tissue (be it benign or cancerous) at the 
surgical margin during radical prostatectomy. The molecular specificity provided by Raman 
spectroscopy could be leveraged to achieve this goal given the right steps towards clinical 
translation. Here, for the first time, we’ve designed, built and integrated a Raman spectroscopy 
system to a surgical robotics platform and demonstrated the feasibility of acquiring measurements 
in vivo in real-time during RP (n=5). The same system was used on ex vivo human prostates (n=20) 
immediately following RP as a proof of concept that Raman spectroscopy can successfully be used 
to distinguish prostate tissue from surrounding organs and tissues with high accuracy.  
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CHAPTER 5 GENERAL DISCUSSION 
The general objective of this thesis was to demonstrate that a tissue characterization system using 
RS can be integrated into the da Vinci surgical platform for RA-RP to characterize tissue 
composition at the surgical margin during RA-RP. The following section will review the 
accomplishments with regards to the objectives laid out earlier and critically discuss each one.  
The first objective set out in this work was the integration of an RS system to the da Vinci surgical 
robotics platform. We have successfully designed an RS system adapted for use in surgical robotics 
and elaborated a workflow compatible with its use clinically in vivo. The system performs RS at 
two excitation wavelengths through a single excitation fiber providing spectra in both the 
fingerprint and high wavenumber spectral regions. Integration with the da Vinci surgical platform 
is mainly accomplished through an adapted probe design which allows it to be inserted through a 
laparoscopic port and grasped by standard robotic grasping instruments. Once the probe is inserted 
and the system ready, the surgeon coordinates with the RS system operator to perform spectral 
measurements. Though this integration is functional, it leaves much room for improvement. 
Surgical robotics offer a platform where technological integration is made easy. Much like an 
iPhone provides developers with sensors, GUI elements, screen space, a camera, and interaction 
paradigms, the da Vinci platform offers a screen on which information can be overlayed, 
centralized controls to manipulate instruments, configurable pedals to toggle between instruments 
or trigger certain functions and more. The current implementation of the RS system to the robot 
fails to optimally take advantage of these features. Most notably, there lacks communication 
between the RS acquisition software and the surgeon/surgical robotics platform. For example, 
pedal based control of RS acquisitions would allow the surgeon to perform spectral acquisitions 
independently rather than providing verbal cues to a system operator. Information on the acquired 
spectra could be displayed to the surgeon directly in his console. It is worth noting that efforts were 
made in this direction in the scope of this project.  A custom protocol was developed for 
communication and control of the RS acquisition software. A TCP/IP server was added to the 
acquisition software with a simple protocol allowing external platforms to trigger Raman 
acquisitions while setting certain parameters and obtaining information back from the system.  
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Automated power/exposure control algorithms (for both excitation wavelengths) allow for optimal 
power to be used for each spectral acquisition without the need for manual intervention. Integration 
of RS to the da Vinci platform could also use some improvement on the mechanical side of things. 
The current probe design uses 6 parallel smooth faces (much like an Allen key) to allow for 
grasping by a robotic clamp. The metal to metal contact between the graspers and the probe is 
slippery and causes the probe to rotate at extreme angles. This was remedied in our case by coating 
the probe with a sterile flexible plastic film before use (Tegaderm) though a more permanent 
solution such as knurling of the metal faces would be more ideal.  
The second objective set out in this project was the collection of ex vivo and in vivo Raman spectra 
from human prostate and peri prostatic organs. The first subobjective here was to collect Raman 
spectra from whole, unprocessed prostates immediately following RP with the objective of 
characterising Raman spectra in different prostatic regions. To do this, a protocol was developed 
wherein the prostate was divided into 5 sub regions (the apex, the base, the 2 lateral lobes, and the 
posterior face). 5 acquisitions were performed for each region on 20 whole human prostates in the 
operating room immediately following RP. When possible, measurements were made on extra-
prostatic tissue available (vas deferens, seminal vesicles). Following this protocol, we successfully 
acquired ~600 spectra on whole human prostate. These spectra serve as the basis for a proof of 
concept that RS can be used to successfully characterize prostate tissue and differentiate between 
prostatic and extra prostatic tissue discussed further. Distinguishing between prostatic and prostatic 
tissue has clinical relevance though it is only a part of the puzzle. Being able to distinguish between 
cancerous prostate tissue and benign prostate tissue at the margin in real time would also have great 
clinical value. The current protocol is not suited to detect cancer as it finds ground truth only in 
visual segmentation of the prostate into gross anatomical region. Pushing this research farther will 
require the introduction of more detailed tissue analysis at spots interrogated for RS (eg. By co-
registration with Histopathology) for use as ground truth. The second subobjective set out in this 
project was the collection of Raman spectra from prostate and peri-prostatic organs in vivo to assess 
the feasibility of distinguishing between prostatic and peri-prostatic tissue intra operatively. Using 
the previously described system in combination with a da Vinci surgical robot we have successfully 
acquired ~20 Raman spectra in vivo during RA-RP from 4 patients. To our knowledge, this is a 
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world first. Though we have shown the feasibility of acquiring RS spectra in vivo, we have 
insufficient data to determine whether or not these spectra can be used to distinguish between 
prostatic and peri prostatic tissue successfully. It also remains to be answered whether spectra 
acquired ex vivo can be used to train models for classification in vivo and vice versa. Answering 
these questions will require acquisition of larger datasets. This rationale lead to the addition of the 
third sub-objective in this category: automating the process of acquiring Raman spectra from 
prostate specimens. Through a collaboration with fourth year engineering students, we successfully 
developed an automated platform capable of acquiring Raman spectra from a flat sample. The 
platform is a highly modified 3D printer which cradles an optical probe and communicates with 
RS acquisition software to perform spectra on points preselected by an operator. Integration was 
successfully tested on 2 human prostate specimens. A typical prostate slice processed manually by 
one of our team members requires roughly an hour of work while the platform accomplishes the 
same results in roughly 20 minutes. Development of this platform is now underway to scale data 
collection across multiple sites with the industrial partners ODS Medical and Intuitive Surgical. 
The final objective of this project was to use the acquired datasets from objective 2 to evaluate the 
potential of RS to provide clinically relevant tissue characterization. Consulting with the 
pathologist (DT) and surgeon (KZ) collaborating on this project, lead to the decision of classifying 
between prostatic and extra prostatic tissue. Spectra acquired from the apex, base, lateral lobes and 
posterior region of ex vivo human prostate were grouped under the label ‘prostate’ while those 
acquired on seminal vesicles and the vas deferens were grouped under the label ‘extra-prostatic’. 
We trained an SVM model with a quadratic kernel on this dataset using 25% holdout validation 
and obtained an accuracy of 91%, a sensitivity of 90.5% and specificity of 96%. These results, 
though preliminary, are promising and indicate Raman has potential as a classification tool in RP. 
Though promising, open questions remain on how these results will translate well in vivo. It 
remains to be shown that models trained ex vivo can be used to perform classifications on similar 
tissue in vivo. To assess performance of these methods in vivo will thus require collection of a large 
dataset in vivo. Classification performance on models trained on an in vivo dataset, models trained 
on an ex vivo dataset, and models trained on mixed in vivo/ex vivo datasets may then be assessed 
and compared. As a preliminary demonstration of the consistency between in vivo and ex vivo 
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measurements, in vivo and ex vivo spectra from the base region of prostate were compared and 
demonstrated to be compatible in the fingerprint region but significant relative intensity differences 
in the high wavenumber region were observed. 
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CHAPTER 6 CONCLUSION AND RECOMMENDATIONS 
A pressing clinical need exists for tissue characterization of prostate tissue during RP : prostate 
tissue is difficult to distinguish from extra prostatic tissue due to the lack of a clear histo RS coupled 
with machine learning holds great potential as a solution to address this need through highly 
sensitive/specific molecular fingerprinting. This work has summarized the engineering, of an RS 
system adapted for use in RARP. A “drop-in” approach was used wherein a probe designed to be 
grasped by robotic grasping instruments is inserted to the patient through a standard laparoscopic 
port and manipulated by the surgeon. This system was used to demonstrate the ability to acquire 
Raman spectra on human prostate and surrounding organs in vivo for the first time on 5 patients.    
A proof of concept study was performed on ex vivo tissue, where it is more feasible to acquire large 
datasets, to assess the potential of RS to provide clinically relevant information in RA-RP. Roughly 
600 spectra were collected from 20 whole human prostates ex vivo immediately following 
resection. Spectra were grouped as either prostatic or extra prostatic tissue and SVM based machine 
learning techniques (quadratic SVM, 25% holdout validation) demonstrated RS’s ability to 
differentiate between prostatic and extra-prostatic tissue with accuracy, sensitivity & specificity > 
90%. The challenges associated with scaling data collection also lead to the development of an 
automated RS platform which was presented in this work. 
 This study holds a few significant limitations. Most notably, the proof of concept addressed 
the need for prostate tissue identification but did not address the need for cancer detection at the 
margin. Our group has demonstrated intracapsular detection with high accuracy but the translation 
of this work to extracapsular detection poses a significant challenge – cancer at the margin is 
relatively rare (1 in 5 cases) and when it is present it is sparse. Pinpointing the spots to interrogate 
and developing a strategy to correlate them with histopathology will therefore be an important 
challenge. Furthermore, research will be required before the technology is mature enough for in 
vivo diagnostic use. Notably, the next logical step will be to acquire far larger datasets both ex vivo 
and in vivo in order to reproduce the preliminary results presented here at scale and test the 
hypothesis that Raman spectra acquired ex vivo and in vivo can be used interchangeably to train 
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classifiers. Finally the robotic integration using a drop-in approach, though functional, hampers the 
clinical workflow in ways that could be avoided with the design of a specialized robotic arm.  
 
 All in all, this work is a promising step forward paving the way for future clinical 
applications of RS in vivo.  The proof of concept in this work focused on the detection of prostate 
tissue though the methods presented here are valid for any context where molecular fingerprinting 
can provide useful  diagnostic information. 
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